Connection

Eric Bartee to Humans

This is a "connection" page, showing publications Eric Bartee has written about Humans.
Connection Strength

0.379
  1. High Levels of Extracellular Potassium Can Delay Myxoma Virus Replication by Preventing Release of Virions from the Endosomes. J Virol. 2023 01 31; 97(1):e0129422.
    View in: PubMed
    Score: 0.033
  2. TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5).
    View in: PubMed
    Score: 0.031
  3. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
    View in: PubMed
    Score: 0.031
  4. Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.
    View in: PubMed
    Score: 0.030
  5. Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.028
  6. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017 06 01; 77(11):2952-2963.
    View in: PubMed
    Score: 0.022
  7. Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):203-12.
    View in: PubMed
    Score: 0.020
  8. Cytokine synergy: an underappreciated contributor to innate anti-viral immunity. Cytokine. 2013 Sep; 63(3):237-40.
    View in: PubMed
    Score: 0.017
  9. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One. 2012; 7(8):e43298.
    View in: PubMed
    Score: 0.016
  10. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1540-51.
    View in: PubMed
    Score: 0.016
  11. Membrane-Associated RING-CH proteins associate with Bap31 and target CD81 and CD44 to lysosomes. PLoS One. 2010 Dec 02; 5(12):e15132.
    View in: PubMed
    Score: 0.014
  12. Cytokine determinants of viral tropism. Nat Rev Immunol. 2009 Sep; 9(9):645-55.
    View in: PubMed
    Score: 0.013
  13. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine. 2009 Sep; 47(3):199-205.
    View in: PubMed
    Score: 0.013
  14. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol. 2009 Jan; 83(2):498-511.
    View in: PubMed
    Score: 0.012
  15. Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol. 2008 Aug; 11(4):378-83.
    View in: PubMed
    Score: 0.012
  16. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2006 Oct; 2(10):e107.
    View in: PubMed
    Score: 0.011
  17. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004 Feb; 78(3):1109-20.
    View in: PubMed
    Score: 0.009
  18. Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer. Int J Mol Sci. 2022 Sep 10; 23(18).
    View in: PubMed
    Score: 0.008
  19. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.008
  20. Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. Am J Transplant. 2021 11; 21(11):3538-3549.
    View in: PubMed
    Score: 0.007
  21. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
    View in: PubMed
    Score: 0.006
  22. Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol. 2013 Apr; 87(8):4445-60.
    View in: PubMed
    Score: 0.004
  23. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res. 2012 May; 36(5):619-24.
    View in: PubMed
    Score: 0.004
  24. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology. 2010 Jun 05; 401(2):266-79.
    View in: PubMed
    Score: 0.003
  25. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 2008 Jul 11; 4(7):e1000099.
    View in: PubMed
    Score: 0.003
  26. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008 May; 38(5):1225-30.
    View in: PubMed
    Score: 0.003
  27. The poxviral RING protein p28 is a ubiquitin ligase that targets ubiquitin to viral replication factories. J Virol. 2005 Jan; 79(1):597-601.
    View in: PubMed
    Score: 0.002
  28. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol. 2003 Jan; 77(2):1427-40.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.